LSALT peptide
Phase 2- Indications
- Acute kidney injury, Cardiac surgery-associated acute kidney injury, Lung inflammation, Liver inflammation, Septic shock
Company intelligence / Profile preview
Arch Biopartners
Toronto, Ontario, Canadaarchbiopartners.com ↗
- Ownership
- Public · ARCH
- Development stage
- Phase 2
01
Overview
Arch Biopartners has advanced its lead candidate LSALT peptide into international Phase II trials for the prevention of cardiac surgery-associated acute kidney injury. The company has demonstrated safety up to a daily dose of 20 mg in healthy volunteers. Recruitment for the CS-AKI trial is ongoing at multiple sites globally, with positive progress reported. Preclinical data support efficacy via DPEP1 pathway inhibition to prevent organ damage from inflammation. Additional programs include cilastatin for toxin-induced AKI and AB569 for antibiotic-resistant infections.
- Therapeutic areas
- ImmunologyInfectious DiseasesPulmonologyNephrology
- Modalities
- Peptides (e.g., LSALT peptide/Metablok)Small molecules (e.g., cilastatin)Antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Collaborations with University of CalgaryUniversity Health Network/Toronto General HospitalUniversity of Cincinnati; no major pharma partnerships disclosed.
04
Financials
- Market cap
- $2.4B
- Total revenue
- $617.9M
- Enterprise value
- $2.3B
Beyond the preview
Go deeper on Arch Biopartners.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arch Biopartners.